1. Academic Validation
  2. Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders

Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders

  • J Med Chem. 2017 Mar 9;60(5):2037-2051. doi: 10.1021/acs.jmedchem.6b01793.
Laurent Gomez 1 Mark Eben Massari 1 Troy Vickers 1 Graeme Freestone 1 William Vernier 1 Kiev Ly 1 Rui Xu 1 Margaret McCarrick 1 Tami Marrone 1 Markus Metz 1 Yingzhou G Yan 1 Zachary W Yoder 1 Robert Lemus 1 Nicola J Broadbent 1 Richard Barido 1 Noelle Warren 1 Kara Schmelzer 1 David Neul 1 Dong Lee 1 Carsten B Andersen 1 Kristen Sebring 1 Kathleen Aertgeerts 1 Xianbo Zhou 1 Ali Tabatabaei 1 Marco Peters 1 J Guy Breitenbucher 1
Affiliations

Affiliation

  • 1 Dart Neuroscience LLC, 12278 Scripps Summit Drive, San Diego, California 92131, United States.
Abstract

A series of potent and selective [1,2,4]triazolo[1,5-a]pyrimidine PDE2a inhibitors is reported. The design and improvement of the binding properties of this series was achieved using X-ray crystal structures in conjunction with careful analysis of electronic and structural requirements for the PDE2a Enzyme. One of the lead compounds, compound 27 (DNS-8254), was identified as a potent and highly selective PDE2a Enzyme inhibitor with favorable rat pharmacokinetic properties. Interestingly, the increased potency of compound 27 was facilitated by the formation of a halogen bond with the oxygen of Tyr827 present in the PDE2a active site. In vivo, compound 27 demonstrated significant memory enhancing effects in a rat model of novel object recognition. Taken together, these data suggest that compound 27 may be a useful tool to explore the pharmacology of selective PDE2a inhibition.

Figures
Products